Leading FDA Drug Approvals in H2 2026 That Could Reshape the Pharma Industry

The second half of 2026 is positioned to bring a significant wave of regulatory activity from the U.S. Food and Drug Administration (FDA), with decisions expected across oncology, infectious diseases, nephrology, neurology, hematology, and rare disorders. The FDA approvals H2 2026 pipeline highlights the industry's growing emphasis on precision medicine, targeted mechanisms, innovative biologics, RNA-based approaches, and treatment formats designed to improve patient convenience.

Oncology Indications: Emerging Therapies Driving H2 2026 Regulatory Activity

The drug approvals H2 2026 outlook includes multiple candidates that could introduce meaningful changes across cancer treatment. Among the therapies attracting attention are Celcuity's gedatolisib, Replimune's vusolimogene oderparepvec (RP1), Merck's subcutaneous KEYTRUDA formulation, and Nuvalent's zidesamtinib.

RP1 is being investigated alongside nivolumab for patients with advanced melanoma and has produced encouraging survival findings in clinical development. Updated Phase II results reported a median overall survival of 32.9 months, strengthening interest in its potential role within advanced melanoma treatment.

Merck's subcutaneous KEYTRUDA QLEX is another notable development for oncology. By moving pembrolizumab administration from the traditional intravenous route toward a subcutaneous delivery approach, the therapy could potentially shorten administration time and make treatment more convenient for patients and healthcare providers. These innovations demonstrate how FDA drug approvals 2026 may increasingly involve not only new mechanisms but also improvements in how established therapies are delivered.

Infectious Disease Indications: HIV Therapies Expanding Treatment Possibilities

Infectious disease treatment is another area expected to attract regulatory attention during the second half of 2026. Gilead Sciences' combination of bictegravir and lenacapavir is among the prominent candidates being evaluated, with a regulatory decision anticipated during the year.

The combination represents an important development in HIV management because it brings together established and innovative antiviral approaches. Lenacapavir, in particular, has generated considerable interest because of its distinctive mechanism and long-acting characteristics. If approved for the proposed indication, the regimen could broaden therapeutic choices for people living with HIV while supporting continued innovation in treatment strategies.

The FDA drug approvals 2026 landscape therefore extends well beyond cancer, reflecting a broader regulatory focus on conditions where treatment durability, convenience, and sustained disease control remain important priorities.

Neurology Indications: Alzheimer’s Disease Diagnostics and Treatment Innovation

Neurology could also experience important developments as regulatory decisions progress through H2 2026. Lantheus' MK-6240 is one candidate drawing attention because of its potential application in Alzheimer's disease assessment through tau positron emission tomography (PET) imaging.

Tau accumulation is a major pathological characteristic associated with Alzheimer's disease, and imaging agents designed to identify tau pathology could contribute to more detailed disease assessment. Improved visualization of disease-related biomarkers may support clinical research, patient evaluation, and the evolving shift toward biomarker-driven neurological care.